A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2025-05-09
DOI
https://doi.org/10.1186/s12916-025-04053-7
Citations
1
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Ling Guan, Junli Wei, Wenzeng Yang, Hong Luo et al.
1 citations
BMC Medicine
Prostate Cancer Treatment and Research
1.52
article

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Ling Guan, Junli Wei, Wenzeng Yang, Hong Luo, Bin Wu, Huixin Ge, Tao Dai, H. Chen, Xuepei Zhang, Xiaolin Lü, Dexin Yu, Xin Yao, Chaohong He, Jitao Wu, Yongdong Zhang, Jiexin Luo, G. Chen, Quanren Wang, Linzhong Cheng, Bin Zheng, Houbao Huang, Tiwu Fan, Xiaofeng Chen, Xiaoping Zhang, Jian Li, Xue Chen, Qilin Wang, Huan Wang, Dingwei Ye, Benkang Shi, Bin Fu, Zhenqiang Xu, Yong Wang
article en
1 citations

Abstract

No abstract available for this paper.
BMC MedicineVol. 23(1)
Hebei Medical University (CN), Central South University (CN), Nanchang University (CN), Guiyang Medical University (CN), Harbin Medical University (CN), Chongqing University (CN), Anhui Medical University (CN), Changzhi Medical College (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Yuhuangding Hospital (CN), Zhengzhou University (CN), Fudan University Shanghai Cancer Center (CN), People 's Hospital of Jilin Province (CN), Zhangzhou Municipal Hospital of Fujian Province (CN), Third Affiliated Hospital of Harbin Medical University (CN), Affiliated Hospital of Guizhou Medical University (CN), Xingtai People's Hospital (CN), Hunan Cancer Hospital (CN), Dongguan People’s Hospital (CN), Wuhan Union Hospital (CN), Sanya Central Hospital (CN), Affiliated Hospital of Hebei University (CN), Jiangsu Hengrui Medicine (China) (CN), Second Affiliated Hospital of Anhui Medical University (CN), First Affiliated Hospital of Bengbu Medical College (CN), Chenzhou First People's Hospital (CN), Chongqing Cancer Hospital (CN), First Affiliated Hospital of Zhengzhou University (CN), Qilu Hospital of Shandong University (CN), First Affiliated Hospital of Nanchang University (CN), First Affiliated Hospital of Wannan Medical College (CN), Southern Medical University (CN), China Medical University (CN)
Good health and well-being
Openalex Percentile: Top 19%
Prostate Cancer Treatment and Research
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.